IUPAC_name = "N"- [3-chloro-4- [(3-fluorophenyl)methoxy] phenyl] -6-
[5- [(2-methylsulfonylethylamino)methyl] -2-furyl]
|3D structure of the Lapatinib molecule
CAS_number = 388082-78-8
ATC_prefix = L01
ATC_suffix = XE07
PubChem = 208908
C = 29 | H = 26 | Cl = 1 | F = 1 | N = 4 | O = 4 | S = 1
molecular_weight = 581.058 g/mol
elimination_half-life = 24 hours
tmax = 3 - 6 hours
legal_AU = S4
legal_US = Rx-only
routes_of_administration = Oral
licence_EU = Tyverb
licence_US = Lapatinib
Lapatinib (INN) or lapatinib ditosylate (USAN) (Tykerb®/Tyverb®, GSK) is an orally active chemotherapeutic drug treatment for
solid tumours such as breast cancer.cite journal |author=Burris HA |title=Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib |journal=Oncologist |volume=9 Suppl 3 |issue= |pages=10–5 |year=2004 |pmid=15163842 |doi= |url=http://theoncologist.alphamedpress.org/cgi/pmidlookup?view=long&pmid=15163842] During development it was known as small moleculeGW572016.Patients who meet specific indication criteria may be prescribed lapatinib as part of combination therapyfor breast cancer.cite web | url = http://newsmax.com/archives/articles/2007/3/13/155445.shtml | title = FDA Approves Advanced Breast Cancer Drug | accessdate = 2008-09-25 | date = 2007-03-13 | work = NewsMax.com Wires | publisher = Associated Press | location = Washington] Pharmacologically, lapatinib is a dual tyrosine kinase inhibitorthat interrupts cancer-causing cellular signals.
March 13, 2007, the FDAapproved lapatinib in combination therapyfor breast cancer patients already using capecitabine(Xeloda®, Roche).
GlaxoSmithKline(GSK) markets the drug under the propriety names Tykerb (mostly US) and Tyverb (mostly Europe).cite press release
title = GlaxoSmithKline receives marketing authorisation in the EU for Tyverb® (lapatinib), the first oral targeted therapy for ErbB2-positive breast cancer
url = http://www.gsk.com/media/pressreleases/2008/2008_pressrelease_10063.htm
accessdate = 2008-06-21] The drug currently has approval for sale and clinical use in the US, Australia,, Bahrain,, Kuwait,, Venezuela, New Zealand,Fact|date=September 2008 South Korea,Fact|date=September 2008 Switzerland,, and the European Union..
Mode of action
Lapatanib inhibits the
tyrosine kinaseactivity associated with two oncogenes, EGFR (epidermal growth factor receptor) and HER2/neu(Human EGFR type 2). Over expression of HER2/neu can be responsible for certain types of high-risk breast cancers in women.cite journal |author= Higa GM & Abraham J |year= 2007 |month= September |title= Lapatinib in the treatment of breast cancer |journal= Expert Review of Anticancer Therapy |volume= 7 |issue= 9 |pages= 1183-92 |publisher= Future Drugs |pmid= 17892419 |doi= 10.1586/14737184.108.40.2063 |url= http://www.expert-reviews.com/doi/abs/10.1586/14737220.127.116.113 |format= log in required] Lapatanib inhibits receptor signal processes by binding to the ATP-binding pocket of the EGFR/HER2 protein kinasedomain, preventing self- phosphorylationand subsequent activation of the signal mechanism (see Receptor tyrosine kinase#Signal transduction).cite journal |author=Nelson MH, Dolder CR |title=Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors |journal=Ann Pharmacother |volume=40 |issue=2 |pages=261–9 |year=2006 |month=February |pmid=16418322 |doi=10.1345/aph.1G387 |url=]
Lapatinib is used as a treatment for women's breast cancer in patients who have HER2-positive advanced breast cancer that has progressed after previous treatment with other chemotherapeutic agents, such as
anthracycline, taxane-derived drugs, or trastuzumab(Herceptin, Genentech).
A 2006 GSK-supported randomized clinical trial on female breast cancer previously being treated with those agents (anthracycline,a taxane and trastuzumab) demonstrated that administrating lapatinib in combination with
capecitabinedelayed the time of further cancer growth compared to regime that use capecitabine alone. The study also reported that risk of disease progression was reduced by 51%, and that the combination therapy was not associated with increases in toxic side effectscite journal |author=Geyer CE, Forster J, Lindquist D, "et al" |title=Lapatinib plus capecitabine for HER2-positive advanced breast cancer |journal=N. Engl. J. Med. |volume=355 |issue=26 |pages=2733–43 |year=2006 |month=December |pmid=17192538 |doi=10.1056/NEJMoa064320 |url=] .
The results from studies like these leave lapatinib with its somewhat complex and rather specific indication — use only in combination with capecitabine for HER2-positive breast cancer afflicted women who have completely responded to previous chemotherapy with anthracycline, taxanes and trastuzumab.
Like many small molecule tyrosine kinase inhibitors, lapatinib is regarded as well tolerated. The most common
side effectsto reported reported are diarrhea, fatigue, nauseaand rashes. cite journal |author=Burris HA, Hurwitz HI, Dees EC, "et al" |title=Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas |journal=J. Clin. Oncol. |volume=23 |issue=23 |pages=5305–13 |year=2005 |month=August |pmid=15955900 |doi=10.1200/JCO.2005.16.584 |url=] In ongoing studies the drug have shown to provoke toxic hepatitis, the toxicity is reversibel when the treatment is stopped.Fact|date=September 2008
* [http://www.cancer.gov/cancertopics/druginfo/lapatinibditosylate Lapatinib Ditosylate - National Cancer Institute]
* [http://www.ctv.ca/servlet/ArticleNews/story/CTVNews/20070603/cancer_drug_070603/20070603?hub=Health Canadian drug touted for advanced breast cancer]
Wikimedia Foundation. 2010.
Look at other dictionaries:
Lapatinib — Nombre (IUPAC) sistemático … Wikipedia Español
Lapatinib — Strukturformel Allgemeines Freiname Lapatinib Andere Namen … Deutsch Wikipedia
lapatinib — A drug used with another anticancer drug to treat breast cancer that is HER2 positive and has advanced or metastasized (spread to other parts of the body) after treatment with other drugs. Lapatinib is also being studied in the treatment of other … English dictionary of cancer terms
lapatinib — noun A particular oral drug used to treat cancer. Syn: lapatinib ditosylate … Wiktionary
Lapatinib — … Википедия
lapatinib ditosylate — A drug used with another anticancer drug to treat breast cancer that is HER2 positive and has advanced or metastasized (spread to other parts of the body) after treatment with other drugs. Lapatinib ditosylate is also being studied in the… … English dictionary of cancer terms
lapatinib ditosylate — noun A particular oral drug used in the treatment of cancer. Syn: lapatinib … Wiktionary
Tykerb — Strukturformel Allgemeines Freiname Lapatinib Andere Namen … Deutsch Wikipedia
Cancer Du Sein — Classification et ressources externes CIM 10 C50 CIM 9 174 ♀ 175 ♂ … Wikipédia en Français
Cancer du sein — Classification et ressources externes Mammographie montrant un cancer du sein à droite. CIM 10 … Wikipédia en Français